碩貝德(300322.SZ):控股子公司終止生物識別模塊項目並轉讓相關股權
格隆匯2月24日丨碩貝德(300322.SZ)公佈,公司於2021年6月22日召開的第四屆董事會第二十二次臨時會議審議通過《關於控股子公司投資生物識別模塊項目的議案》,同意江蘇凱爾在廬江高新區投資年產1億片生物識別模塊項目。年產1億片生物識別模塊項目是公司指紋模組業務的擴產項目,自項目實施以來,公司積極推進項目的設備採購、生產場地改造等工作,並逐步將其他地區相關的生產線搬遷至廬江。目前,市場情況發生較大變化,公司相關產品的營業收入、毛利率出現大幅下滑,項目繼續實施存在較大的不確定性。經審慎考慮,公司擬終止項目投資並轉讓相關股權。公司控股子公司江蘇凱爾生物識別科技有限公司(簡稱“江蘇凱爾”)擬向蘇州靈動佳芯科技有限公司、蘇州承與萱企業管理有限公司或其指定的第三方(簡稱“受讓方”)轉讓安徽凱爾通訊科技有限公司(簡稱“安徽凱爾”)80.20%股權,具體受讓方及各方受讓比例尚存在不確定性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.